ArticleResearch and practice in thrombosis and haemostasis2026
An exploratory plasma-based functional assay for phenotypic characterization of fibrinolysis in dysfibrinogenemia.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Another step toward phenotypic characterization of hereditary dysfibrinogenemia?Research and practice in thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Congenital dysfibrinogenemia exhibits heterogeneous clinical phenotypes, ranging from bleeding to thrombosis. However, conventional fibrinogen assays primarily evaluate clot formation alone. Genetic analyses are informative but do not fully explain phenotypic diversity, particularly with respect to clot formation-lysis behavior. Objectives: This study developed a novel plasma-based functional assay for exploratory characterization of integrated clot formation-lysis kinetics in congenital dysfibrinogenemia. Methods: The Clauss fibrinogen assay was modified by supplementing recombinant tissue-type plasminogen activator and Lys-plasminogen to enable monitoring of the fibrinolysis phase following clot formation, termed the CLySis assay. Clot-fibrinolysis waveform analysis defined the time to fibrinolysis ( Results: The CLySis assay enabled stable monitoring of clot formation and subsequent fibrinolysis. The Conclusion: The CLySis assay provides a functional, genotype-independent approach for exploratory characterization of clot-lysis behavior in congenital dysfibrinogenemia. This assay may support future phenotypic analyses of dysfibrinogenemia, complementing conventional genetic evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.